Varivax is a live, attenuated varicella-zoster vaccine, a weakened form of the chickenpox virus.
It is a vaccine indicated for active immunization for the prevention of varicella (ChickenPox) in individuals 12 months of age or older.
Varivax is administered by subcutaneous injection. Each dose is approximately 0.5 mL after reconstitution.
A second dose must be given at least 3 months after the first shot.
Additionally, a second dose should be given to those who first get the vaccine when they are 13 years.
According to the CDC, due to the nature of Varivax, a weakened live vaccine, it is possible for the recipient of this vaccine to develop shingles later in life.